Chronic heart failure (CHF) is a complex clinical syndrome caused by abnormal changes in cardiac structure and/or function, resulting in impaired ventricular systolic and/or diastolic function, which is the end stage of heart disease development, and how to better treat CHF, reduce its mortality and improve the quality of life of CHF patients is an important clinical problem to be solved. For chronic heart failure, the common clinical treatment protocol is the “golden triangle”, i.e. angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) + beta-blocker + aldosterone receptor antagonist. Recent studies have shown that SGLT-2i has a favorable effect on improving the prognosis of CHF. 2021 European Society of Cardiology (ESC) recommends the addition of SGLT-2i in CHF patients if not contraindicated, which can significantly reduce mortality in CHF patients. Hyperbaric oxygen therapy, can be used as an adjunctive treatment for many ischemic and hypoxic diseases. The effects of hyperbaric oxygen therapy on the circulatory system include: 1. slowed heart rate (10%-30%). 2. reduced cardiac contractility and lower cardiac output. 3. decreased myocardial oxygen consumption (20%). 4. increased blood pressure and smaller pulse pressure difference. 5. decreased coronary blood volume. The possibility of hyperbaric oxygen therapy as an adjunctive therapy for chronic heart failure is a very interesting topic. It has been reported that hyperbaric oxygen therapy can increase matrix metalloproteinases and vascular endothelial growth factor, induce angiogenesis and improve perfusion in ischemic areas. It has been suggested that hyperbaric oxygen therapy can improve myocardial blood perfusion, vascular endothelial dysfunction and myocardial microcirculation.